Fenipentol (1-Phenyl-1-pentanol): Mechanisms, Evidence & Protocols

Executive Summary: Fenipentol (CAS 583-03-9), a naturally derived and synthetically accessible small molecule, modulates estrogen receptor α (ESR1) with a binding affinity of -4.75 kcal/mol and promotes bile acid secretion in controlled studies (source: product_spec). Toxicological assessments in rats indicate a NOAEL of 10 mg/kg/day after 13 weeks, supporting its safety in preclinical protocols (source: Ford et al. 1983). Fenipentol enhances pancreatobiliary fluid volume (292%–722%) and lipase activity (up to 5-fold) via duodenal delivery (source: workflow_recommendation). It is highly soluble in DMSO, ethanol, and water, and requires specific storage conditions to maintain stability (source: product_spec). Research has elucidated its modulation of inflammation- and metabolism-related pathways, positioning Fenipentol as a valuable tool for gastrointestinal physiology studies (source: mechanistic_review).

Biological Rationale

Fenipentol (1-Phenyl-1-pentanol) is primarily sourced from the cortex of Ligusticum chuanxiong, a traditional medicinal plant with established use in hepatobiliary and cardiovascular disorders (source: Differential Volatiles in Chuanxiong Rhizome). Its consistent presence in cortex fractions links it to regional bioactivity in herbal preparations. The molecule’s ability to increase bile acid secretion and regulate gastrointestinal secretions underpins its relevance in digestive and hepatic research (source: mechanistic_review). Fenipentol’s activity as a choleretic agent for pancreatic secretion research and as a modulator of bicarbonate secretion has been demonstrated in both historical clinical and modern in vitro models (source: mechanistic_review).

Mechanism of Action of Fenipentol

Biochemically, Fenipentol interacts with estrogen receptor α (ESR1), exhibiting a molecular docking binding affinity of -4.75 kcal/mol (source: product_spec). This interaction suggests a regulatory role in hormone-responsive signaling pathways. Proteomic and transcriptomic analyses in related compounds indicate additional modulation of Wnt/β-catenin and TGF-β1 pathways, especially in hepatic stellate cells (source: Buakaew et al. 2024). In gastrointestinal models, Fenipentol promotes pancreatobiliary fluid secretion and increases enzymatic activity, notably lipase, supporting its role in digestive function (source: mechanistic_review).

Evidence & Benchmarks

• Fenipentol increases pancreatobiliary fluid volume by 292%–722% after duodenal intubation in vivo (source: mechanistic_review).
• Lipase enzymatic activity is enhanced up to fivefold following Fenipentol administration (source: mechanistic_review).
• The no-observed-adverse-effect level (NOAEL) is established at 10 mg/kg/day in 13-week rat studies (source: Ford et al. 1983).
• Reversible effects at 160 mg/kg/day include slowed weight gain and mild proteinuria, with no histopathological changes (source: Ford et al. 1983).
• Fenipentol is soluble at ≥32 mg/mL in DMSO, ≥16.4 mg/mL in ethanol, and ≥31.8 mg/mL in water (source: product_spec).
• Binding affinity for ESR1 is -4.75 kcal/mol by molecular docking (source: product_spec).
• Downregulation of fibrosis markers (COL1A1, COL4A1, SMAD2/3, MMP2) observed in related phenylpentanol compounds in hepatic stellate cells (source: Buakaew et al. 2024).

This article updates prior guidance from Fenipentol (1-Phenyl-1-pentanol): Data-Driven Solutions by furnishing new quantitative NOAEL and mechanistic insights; it also extends the mechanistic discussion in Fenipentol (1-Phenylpentan-1-ol): Mechanistic Frontiers by integrating recent hepatobiliary and ESR1 binding data.

Applications, Limits & Misconceptions

Fenipentol is applied as a choleretic agent in pancreatic secretion and bicarbonate modulation studies. It is valuable in gastrointestinal physiology research where precise regulation of bile acid and enzymatic secretion is required (source: mechanistic_review). Fenipentol's historical use in duodenal intubation protocols and its safety margin support its role in translational research workflows (source: product_spec). However, its efficacy outside of these domains, such as direct anti-fibrotic therapy in clinical settings, remains unproven. The molecule is not a direct anti-microbial, nor is it suited as a systemic anti-inflammatory agent based on current evidence (source: Ford et al. 1983).

Common Pitfalls or Misconceptions

• Fenipentol is not validated for direct anti-fibrotic therapy in vivo; supporting data are based on related analogs and in vitro models only (source: Buakaew et al. 2024).
• It should not be used as a general antioxidant or broad-spectrum anti-inflammatory agent (source: workflow_recommendation).
• Systemic toxicity data are limited to subchronic oral studies in rats; extrapolation to higher mammals or chronic exposure remains unsupported (source: Ford et al. 1983).
• Long-term solution storage is not recommended; instability may affect experimental outcomes (source: product_spec).
• Fenipentol’s effect profile is not generalizable to all phenylalkanols or turmeric derivatives (source: workflow_recommendation).

Workflow Integration & Parameters

For robust experimental outcomes, researchers should adhere to strict handling and dosing protocols. Fenipentol is available from APExBIO as SKU C8318 (product page), with defined solution stability and storage requirements: 4°C, desiccated, and protected from light. Solutions should be prepared fresh and used promptly.

Protocol Parameters

• cell viability/proliferation assay | 1–10 μM | cell-based models (LX-2, HepG2) | optimal for estrogenic and secretory pathway modulation | workflow_recommendation
• NOAEL (rat, oral, 13 weeks) | 10 mg/kg/day | preclinical in vivo | benchmark for systemic safety | peer-reviewed_toxicology (Ford et al. 1983)
• solubility (DMSO) | ≥32 mg/mL | compound preparation | ensures high-concentration stock solutions | product_spec (APExBIO)
• solution storage | <48 hours at 4°C, protected from light | all applications | prevents compound degradation and assay drift | workflow_recommendation
• duodenal intubation (historical) | 1–5 mg/kg | animal pancreatobiliary studies | maximizes choleretic effect | mechanistic_review (article)

Conclusion & Outlook

Fenipentol (1-Phenyl-1-pentanol) is a structurally simple but mechanistically rich agent for gastrointestinal and hepatobiliary research. Its robust safety margin, precise solubility profile, and defined mechanism of ESR1 engagement make it an ideal reference for choleretic and secretory pathway investigations. For expanded mechanistic insight, readers are referred to Fenipentol: Mechanistic Insights and Biochemical Applications, which this article updates with new safety and solubility benchmarks. Ongoing research is expected to further clarify Fenipentol’s translational potential within metabolism and inflammation-related pathways, but its use should remain within validated experimental boundaries (APExBIO).